# VitsGen Therapeutics

Source: https://onco.cc/companies/vitsgen-therapeutics/  
OnCo record `vitsgen-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VitsGen Therapeutics is a Chinese company making radioactive medicines that home in on proteins found on tumours. Its lead, 177Lu-FAP-VG11, targets FAP in the tissue around tumours and has orphan drug status for soft tissue sarcoma.

## Summary

VitsGen says it has developed targeted radiopharmaceuticals since 2021, with teams in China and the United States, and lists FAP, PSMA and carbonic anhydrase IX (CA9) programmes. The FDA record gives the address of VitsGen Therapeutics Inc. in the economic development zone of Tengzhou, Zaozhuang, Shandong. Its lead, 177Lu-FAP-VG11, is the FAP-targeting ligand FAP-VG11 chelated to lutetium-177. China's NMPA Center for Drug Evaluation accepted an IND application for it from Shandong VitsGen Pharmaceutical Co., Ltd. on 12 August 2026, and an investigator-initiated trial at Shandong Cancer Hospital and Institute (NCT07808177) began in September 2026. On 22 October 2026 the FDA granted orphan drug designation for soft tissue sarcoma.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: VitsGen Therapeutics Inc.; VitsGen; Shandong VitsGen Pharmaceutical Co., Ltd.
- HQ: Tengzhou, Shandong
- Type: radiopharma
- Website: https://www.vitsgen.com/

## Notes

- The company's founding year and financing are not stated in the pages read. Read on 4 November 2026.

## Sources

- Official website: https://www.vitsgen.com/
- FDA orphan designation announcement, October 2026: https://www.vitsgen.com/News?article_id=151
- China IND acceptance, September 2026: https://www.vitsgen.com/News?article_id=149
- FDA orphan designation, soft tissue sarcoma, 22 October 2026: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1153626

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [Lutetium-177 radioligand therapy](https://onco.cc/technologies/lu177-radioligand-therapy/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)
- targets: [FAP](https://onco.cc/targets/fap/)
- drugs: [177Lu-FAP-VG11](https://onco.cc/drugs/lu177-fap-vg11/)

---
JSON: https://onco.cc/api/v1/entities/vitsgen-therapeutics.json